Group 1 - The 2025 China International Service Trade Fair (CIFTIS) is being held from September 10 to September 14 in Beijing, with a significant participation rate of 53% from Fortune Global 500 and industry-leading companies in the health and sanitation services sector [1] - The international participation rate at the fair reached 49%, indicating a growing interest in collaboration between domestic and foreign medical enterprises [1] - Several multinational medical companies expressed optimism about the potential for Sino-foreign cooperation and their commitment to deepening their presence in the Chinese market [1] Group 2 - Philips showcased its new ElitionAI+ intelligent MRI and the Azurion ClarityIQ interventional imaging platform, which has been clinically validated on nearly 20,000 patients, achieving a 70% reduction in radiation dose during interventional procedures [2] - Johnson & Johnson celebrated its 40th anniversary in China by presenting several breakthrough innovative products, including the Impella CP with SmartAssist and the innovative drug Nikalizumab, which are making their debut at the fair [2] - Other notable products included Siemens' photon-counting CT and GE Healthcare's MRI equipment tailored for brain and heart treatment, demonstrating advanced technology and market influence [2] Group 3 - Six Fortune Global 500 companies, including GE Healthcare, Siemens Healthineers, and Johnson & Johnson, have consistently participated in the fair, highlighting their commitment to the Chinese market [3] - Philips has been operating in China for 40 years and plans to establish its China R&D headquarters in Beijing by 2025, reflecting its long-term commitment to the local market [4] - Johnson & Johnson noted that recent policies encouraging innovation in China have created a favorable environment for multinational companies, significantly accelerating the approval and market entry of innovative medical products [4][5] Group 4 - The reform of China's drug review system has allowed Johnson & Johnson to expedite the approval of seven innovative drugs and twelve indications in 2024, including the global first approval for certain indications of its products [5] - The increasing awareness of public health, advancements in medical technology, and reforms in China's healthcare system are driving rapid development in the health sector, providing a conducive environment for business growth [5] - Companies are committed to leveraging global innovations while aligning with local market needs, emphasizing their dedication to high-quality healthcare development in China [5]

此次参展，两款重磅产品首次亮相服贸会：一是心力衰竭治疗领域的Impella CP with SmartAssist介入式 左心室辅助泵；二是尼卡利单抗注射液，其在中国注册申请目标适应症为治疗特定抗体阳性的全身型重 症肌无力成人及12岁以上青少年患者。 经济观察网9月10日，强生公司携旗下医疗科技与创新制药两大业务板块参展2025年中国国际服务贸易 交易会，重点呈现数十款全球领先突破性创新产品、多治疗领域精准化医疗解决方案，以及融合全球产 研能力与中国临床智慧的本土化创新成果。 ...